FindTrial
Sign In

Evaluating the effects of treatmen with amitriptyline as a tricyclic antidepressant drug on serum prolactin levels in patients with chronic migraine and its relation with patient’s quality of life and function

Evaluating the effects of treatmen with amitriptyline as a tricyclic antidepressant drug on serum prolactin levels in patients with chronic migraine and its relation with patient’s quality of life and function

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211013052758N1
Enrollment
20
Registered
2021-11-03
Start date
2021-11-02
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine.

Interventions

Intervention group:patients with migraine with typic aura or without aura.

Sponsors

Semnan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with migraine without aura who need preservative treatment patients with migraine with classic aura who need preservative treatment

Exclusion criteria

Exclusion criteria: anything that might affect serum prolactin levels in patients including medications or comorbidities contraindications of TCAs prescription such as heart disease or anaphylaxia

Design outcomes

Primary

MeasureTime frame
Effects of amytriptyline induced serum prolactin level changes on migraine patients quality of life. Timepoint: before starting treatment and 2 month after starting treatment with amitriptyline. Method of measurement: prolactin serum level test (ELISA) - Headache impact test (HIT) questionier.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNegar Emadeddin

Semnan University of Medical Sciences

negaremadi.92@gmail.com+98 21 8867 1907

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026